78441-69-7

Basic information

• Product Name: 2-(DIMETHYLAMINOMETHYL)-4-THIAZOLEMETHANOL
• Synonyms: 4-THIAZOLEMETHANOL, 2-[(DIMETHYLAMINO)METHYL]-;2-(DIMETHYLAMINOMETHYL)-4-THIAZOLEMETHANOL;(2-DIMETHYLAMINOMETHYL-THIAZOL-4-YL)-METHANOL;CBI-BB ZERO/005461
• CAS NO: 78441-69-7
• Molecular Formula: C₇H₁₂N₂OS
• Molecular Weight: 172.25
• EINECS: 1312995-182-4
• Product Categories: Alkohols;Amines;Heterocycles;Impurities;Intermediates;Sulfur & Selenium Compounds
• Mol File: 78441-69-7.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 273.114 °C at 760 mmHg
• Flash Point: 118.976 °C
• Appearance: /
• Density: 1.209 g/cm³
• Vapor Pressure: 0.00285mmHg at 25°C
• Refractive Index: 1.574
• Storage Temp.: 2-8°C
• PKA: 13.22±0.10(Predicted)
• CAS DataBase Reference: 2-(DIMETHYLAMINOMETHYL)-4-THIAZOLEMETHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(DIMETHYLAMINOMETHYL)-4-THIAZOLEMETHANOL(78441-69-7)
• EPA Substance Registry System: 2-(DIMETHYLAMINOMETHYL)-4-THIAZOLEMETHANOL(78441-69-7)

Safety Data

• Hazard Codes: N
• Statements: 51/53
• Safety Statements: 61
• Hazardous Substances Data: 78441-69-7(Hazardous Substances Data)

Usage

Description

2-(DIMETHYLAMINOMETHYL)-4-THIAZOLEMETHANOL, also known as Nizatidine EP Impurity J, is an organic compound with the molecular formula C7H12N2OS. It is characterized by its thiazole ring and dimethylaminomethyl group, which contribute to its chemical properties and potential applications.

Uses

Used in Pharmaceutical Industry:
2-(DIMETHYLAMINOMETHYL)-4-THIAZOLEMETHANOL is used as an impurity in the histamine H2-receptor antagonist Nizatidine (N598500) for the treatment of conditions such as peptic ulcers, gastroesophageal reflux disease (GERD), and other acid-related disorders. Its presence as an impurity is significant because it can affect the safety, efficacy, and quality of the final drug product. Ensuring the control and removal of this impurity is crucial for maintaining the therapeutic benefits and minimizing potential side effects of Nizatidine.

InChI:InChI=1/C7H12N2OS/c1-9(2)3-7-8-6(4-10)5-11-7/h5,10H,3-4H2,1-2H3

Upstream product

• 92759-37-0 4-Hydroxy-4-(chloromethyl)-2-<(dimethylamino)methyl>thiazoline 
• 82586-66-1 ethyl 2-(dimethylaminomethyl)-4-thiazolecarboxylate 

Downstream Products

• 78441-62-0 4-[[(2-aminoethyl)thio]-methyl]-N,N-dimethyl-2-thiazolemethanamine 
• 199599-68-3 2-dimethylaminomethylthiazole-4-carboxaldehyde 

Relevant articles and documents

Clean preparation method of 4-hydroxymethylthiazole and its intermediate

The invention discloses a clean preparation method of 4-hydroxymethylthiazole and its intermediate. The clean preparation method includes, taking compound I as an example, the steps of in a solvent, subjecting compound IV and an alkali metal hypohalite to

HYDRAZONE DERIVATIVE

A compound represented by the following formula (I): wherein R1 represents hydrogen, aryl which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, etc.; R2 represents hydrogen, aryl which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, etc.; R3 represents hydrogen, etc.; Ar represents a divalent group derived from aromatic hydrocarbon, etc.; X represents a single bond, linear or branched alkylene having from 1 to 3 carbon atoms which may have a substituent, etc.; and G represents halogen, a saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, etc., a salt thereof or a solvate thereof; and an agent for inhibiting aggregation and/or deposition of an amyloid protein or an amyloid-like protein, which comprises the compound, a salt thereof or a solvate thereof

2,3 Disubstituted- (5,6)-heteroarylfused-pyrimidine-4-ones

The present invention relates to novel compounds of the formula I, described above, and their pharmaceutically acceptable salts, and pharmaceutical compositions and methods of treating neurodegenerative and CNS-trauma related conditions.